Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Is Mesoblast Limited's (ASX:MSB) Shareholder Ownership Skewed Towards Insiders?
01:32am, Friday, 17'th Jul 2020
A look at the shareholders of Mesoblast Limited (ASX:MSB) can tell us which group is most powerful. Generally...
Mesoblast expands compassionate use COVID-19 program
04:18pm, Friday, 10'th Jul 2020
Mesoblast has developed a cellular therapy that may significantly reduce deaths among the most severely sick COVID-19 patients. CEO Dr. Fred Grossman joins Yahoo Finance's On the Move to discuss what
Here's Why Mesoblast Stock Rose Over 18% Today
08:37pm, Monday, 06'th Jul 2020
The Australian biopharma earned an important clearance to treat COVID-19 patients in the United States, which could be a sign of things to come.
NEW YORK, July 06, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that an expanded access protocol (EAP) has been initiated in the United States for.
Don't Forget Cytodyn's Other Prospects
03:12pm, Thursday, 25'th Jun 2020
Coronavirus results to be reported in July. Anecdotal results are excellent. HIV results are excellent. BLA has been applied for. 12 ladies with triple negati
Remestemcel-L Improves Respiratory and Functional Outcomes in Patients With Inflammatory Lung Disease
10:00am, Monday, 01'st Jun 2020
NEW YORK, June 01, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that.
Is Mesoblast Limited (MESO) A Good Stock To Buy?
02:49am, Sunday, 31'st May 2020
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev
Mesoblast Limited (MESO) Q3 2020 Earnings Call Transcript
03:00pm, Thursday, 28'th May 2020
Hello, and welcome to the financial results for the period ended March 31, 2020, and corporate update for Mesoblast. Before we begin, let me remind you that in today's conference call the company wil
Mesoblast Reports Strong Financial Position and Substantial Operational Progress For the Period Ended March 31, 2020
09:53pm, Wednesday, 27'th May 2020
NEW YORK, May 27, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial,.
Mesoblast to Host Analyst Call on Financial Results for Period Ended March 31, 2020
10:00am, Tuesday, 26'th May 2020
NEW YORK, May 26, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the.
Key points: Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy, publishes three.
Who Has Been Buying Mesoblast Limited (ASX:MSB) Shares?
12:03am, Wednesday, 20'th May 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Here's Why Mesoblast Is Soaring Today
06:23pm, Wednesday, 13'th May 2020
Shares of Mesoblast (NASDAQ: MESO) rose as much as 27.2% today after the company announced the pricing of an offering of common stock. The stem cell developer will issue up to 43 million shares of co
Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS
10:00am, Wednesday, 13'th May 2020
Mesoblast Limited (Nasdaq: MESO; ASX:MSB), a leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a capital raising of US$90 million¹ (A$138 mil
First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
10:00am, Wednesday, 06'th May 2020
NEW YORK, May 06, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the first patients have.
